Literature DB >> 13316673

Ansolysen in the treatment of arterial hypertension.

A DAVIGNON, G LEMIEUX, J GENEST.   

Abstract

Entities:  

Keywords:  HYPERTENSION/therapy; MUSCLE RELAXANTS/therapeutic use

Mesh:

Substances:

Year:  1956        PMID: 13316673      PMCID: PMC1824342     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  9 in total

1.  Long-term management of hypertension with pentolinium tartrate (ansolysen).

Authors:  A AGREST; S W HOOBLER
Journal:  J Am Med Assoc       Date:  1955-03-19

2.  The treatment of essential hypertension with pentolinium tartrate combined with Rauwolfia alkaloids.

Authors:  C W C BAIN; F ASHTON; B P JONES
Journal:  Br Med J       Date:  1955-04-02

3.  [Administration of hexamethonium to patients with severe hypertension].

Authors:  J GENEST; R ROBILLARD; G TREMBLAY; L ADAMKIEWICZ
Journal:  Union Med Can       Date:  1954-11

4.  A clinical appraisal of pentapyrrolidinium (M&B 2050) in hypertensive patients.

Authors:  E D FREIS; E A PARTENOPE; L S LILIENFIELD; J C ROSE
Journal:  Circulation       Date:  1954-04       Impact factor: 29.690

5.  Methonium compounds in the angina of hypertension.

Authors:  A E DOYLE; J A KILPATRICK
Journal:  Lancet       Date:  1954-05-01       Impact factor: 79.321

6.  The methonium.

Authors:  W D M PATON; E ZAIMIS
Journal:  Pharmacol Rev       Date:  1952-09       Impact factor: 25.468

7.  New sympathicolytic agents.

Authors:  R D H MAXWELL; A J M CAMPBELL
Journal:  Lancet       Date:  1953-03-07       Impact factor: 79.321

8.  Pharmacology of M. & B. 2050.

Authors:  R WIEN; D F J MASON
Journal:  Lancet       Date:  1953-03-07       Impact factor: 79.321

9.  Practical details of the treatment of hypertension by hexamethonium salts and by pentamethylene 1:5-bis-N-(N-methylpyrrolidinium) bitartrate (M. & B. 2050A).

Authors:  F H SMIRK
Journal:  N Z Med J       Date:  1953-10
  9 in total
  1 in total

1.  Management and concept of human arterial hypertension.

Authors:  J GENEST
Journal:  Can Med Assoc J       Date:  1956-10-15       Impact factor: 8.262

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.